Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma

Kuehrer, Nadja and Huebner-Resch, Irene and Mayr, Roman and Agaimy, Abbas and Kronbichler, Andreas and Hartmann, Arndt and Schmidinger, Manuela and Pichler, Renate (2025) Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma. CLINICAL & EXPERIMENTAL METASTASIS, 42 (5): 47. ISSN 0262-0898, 1573-7276

Full text not available from this repository. (Request a copy)

Abstract

Fumarate hydratase-deficient renal cell carcinoma (FHdRCC) has been classified under the new category of molecularly defined RCCs according to the WHO classification 2022. Although rare, FHdRCC is an aggressive malignancy with a high metastatic potential and poor prognosis, even at early stages. Due to its low incidence, no standard therapeutic regimen has been established to date. Several phase 2 clinical trials are evaluating combinations of targeted therapies in patients with advanced/metastatic disease. These include immune checkpoint inhibitors (nivolumab, tislelizumab, sintilimab, avelumab), multi-tyrosine kinase inhibitors (cabozantinib, erlotinib, lenvatinib, axitinib, vandetanib), and PARP inhibitors (talazoparib). The most promising combinations are nivolumab/cabozantinib (N = 5, objective response rate (ORR): 100%), lenvatinib/tislelizumab (N = 14, ORR: 93.3%), bevacizumab/erlotinib (N = 43, ORR: 72%), and sintilimab/axitinib (N = 19, ORR: 63.1%). In this review, we will provide a detailed overview of ongoing clinical trials, highlighting the roles of metabolic and epigenetic reprogramming, as well as pro- oncogenic signaling, which together form the backbone for emerging novel targeted treatment strategies. Targeting these specific signaling pathways will shift the therapeutic landscape toward personalized medicine in metastatic FHdRCC.

Item Type: Article
Uncontrolled Keywords: HEREDITARY LEIOMYOMATOSIS; CANCER; INHIBITION; GENE; SUCCINATION; EXPRESSION; HISTONE; FH; Fumarate hydratase deficient renal cell carcinoma; Hereditary leiomyomatosis and renal cell cancer; Renal cell carcinoma (RCC); Targeted therapy; Immunotherapy; Bevacizumab; Erlotinib; Fumarate hydratase
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 23 Sep 2026 07:46
Last Modified: 23 Sep 2026 07:46
URI: https://pred.uni-regensburg.de/id/eprint/67402

Actions (login required)

View Item View Item